Clinical Trial Update: Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

The phase 1 trial of dovitinib in combination with bortezomib and dexamethasone for relapsed/refractory multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Dovitinib (dovitinib)

Snippet

Sponsor: University of Florida | Conditions: Multiple Myeloma | Phase 1 | Status: WITHDRAWN